Core Insights - The company reported a strong performance in Q3 2025, with revenue reaching 902 million yuan, a year-on-year increase of 30.72%, and a net profit of 92.83 million yuan, up 38.68% [1] - The company has transformed from a channel-driven model to a research-driven approach since its listing in 2021, significantly increasing its patent portfolio to 676 [1][2] - The company has established a modern intelligent manufacturing system, enhancing production efficiency and product consistency [2] Financial Performance - In Q3 2025, the company achieved a record high in both revenue and profit, with a non-net profit of 85.80 million yuan, marking a substantial growth of 62.68% year-on-year [1] - The company's self-owned brand products generated 1.751 billion yuan in revenue, accounting for nearly 60% of total revenue, with a gross margin of 56% [2] Innovation and R&D - The company has launched over 100 new products annually, including innovative devices like the blood glucose and uric acid integrated machine and a non-invasive ventilator [1] - The establishment of three research institutes and a research team of nearly 400 people underscores the company's commitment to innovation [1] International Expansion - The company's overseas business revenue grew by over 200% in the first half of 2025, with products now available in over 60 countries and regions [2] - Recent acquisitions, including Shanghai Huazhou and Hong Kong Ximan, aim to expand the company's international distribution network [2] Industry Positioning - The company has successfully transitioned into a comprehensive medical device enterprise that integrates research innovation, intelligent manufacturing, and multi-channel marketing [2] - Future growth is expected to be driven by the expansion of core product categories, deepening of self-owned brands, and the advancement of international strategies [2]

Core Insights - Kefu Medical reported a strong performance in Q3 2025, achieving a revenue of 902 million yuan, a year-on-year increase of 30.72%, and a net profit attributable to shareholders of 92.83 million yuan, up 38.68% year-on-year [1] - The company is accelerating its international expansion by submitting a listing application to the Hong Kong Stock Exchange, aiming to become a dual-listed company, which will enhance its global financing channels and brand influence [1][2] - Kefu Medical is focusing on a dual-driven strategy of "product innovation + channel upgrade," with its core categories showing steady growth, ranking second among home medical device companies in China, with rehabilitation aids ranked first [1][2] Financial Performance - In Q3 2025, Kefu Medical achieved a net profit of 92.83 million yuan, reflecting a 38.68% increase year-on-year [1] - The company's net profit excluding non-recurring items reached 85.80 million yuan, marking a significant year-on-year growth of 62.68% [1] Product Innovation - Kefu Medical has increased its R&D investment, launching new products such as portable ventilators, dual glucose and uric acid test strips, a new generation of bone conduction hearing aids, and tunnel-type blood pressure monitors, enhancing its "home health management" product matrix [1][2] - The new generation bone conduction hearing aid developed in collaboration with Tencent has improved voice clarity and intelligibility by 85% in complex noise environments, utilizing deep learning acoustic scene recognition technology [2] International Expansion - The funds raised from the Hong Kong listing will primarily be used for global brand building, overseas channel expansion, and innovation R&D, strengthening the company's international operational capabilities [2] - The move to list in Hong Kong is expected to optimize the company's capital structure and enhance its competitiveness and brand strength in the global home medical device market [2] Industry Outlook - The home medical device industry is experiencing structural growth opportunities due to the "Healthy China 2030" strategy and the aging population trend [2] - Kefu Medical aims to leverage its full industry chain layout and brand advantages to achieve high-quality growth in both domestic and international markets [2]

Company Overview - Kewei Medical (SZ 301087) announced on October 29 that its 19th meeting of the second board of directors was held via communication, discussing the proposal for the fourth extraordinary general meeting of shareholders in 2025 [1] - As of the report, Kewei Medical has a market capitalization of 9.1 billion yuan [1] Financial Performance - For the first half of 2025, Kewei Medical's revenue composition shows that medical health products accounted for 96.79% of total revenue, while other businesses contributed 3.21% [1]

Group 1 - The core viewpoint of the article highlights that Kewei Medical (SZ 301087) reported its Q3 performance, showing a revenue increase of 6.63% year-on-year, reaching approximately 2.398 billion yuan [1] - The net profit attributable to shareholders increased by 3.3% year-on-year, amounting to about 260 million yuan [1] - Basic earnings per share rose by 3.23% year-on-year, reaching 1.28 yuan [1] Group 2 - As of the report, Kewei Medical has a market capitalization of 9.1 billion yuan [1] - The article also notes a significant market trend, indicating that the A-share market has surpassed 4000 points, marking a resurgence after a decade of stagnation, with technology leading the market's transformation [1]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-077 可孚医疗科技股份有限公司 关于调整2025年度日常关联交易预计额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 可孚医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第二届董事会第十四次会议及第二届监事会第十四次会议，审议通过了《关于 2025 年度日常关联交易预计的议案》，公司预计 2025 年度因业务发展及日常经 营的需要与关联方湖南楮墨仓科技有限公司（以下简称"楮墨仓"）发生日常关 联交易不超过 240 万元。 公司于 2025 年 10 月 29 日召开第二届董事会第十九次会议，审议通过了《关 于调整 2025 年度日常关联交易预计额度的议案》。鉴于市场及天气情况变化， 公司拟调整 2025 年度日常关联交易预计金额，预计 2025 年度向楮墨仓采购商品 的交易金额由 240 万元调整为 340 万元。关联董事张敏先生已回避表决。该事项 已经公司独立董事专门会议审议通过。根据《深圳证券交易所创 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-079 可孚医疗科技股份有限公司 3、拟变更会计师事务所的原因：可孚医疗科技股份有限公司（以下简称"公 司"）根据自身发展需求、整体审计工作需要及《国有企业、上市公司选聘会计 师事务所管理办法》，经履行公司选聘程序，拟聘任安永华明为公司 2025 年度 审计机构。 4、公司已就拟变更会计师事务所的相关事宜与前后任会计师事务所进行了 沟通，前后任会计师事务所已明确知悉本次拟变更事项并确认无异议。公司董事 会、审计委员会对本次拟变更审计机构的事项均不存在异议，该事项尚需提交公 司股东会审议。 5、本次变更会计师事务所符合财政部、国务院国资委、证监会印发的《国 有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 可孚医疗科技股份有限公司（以下简称"公司"或"可孚医疗"）于 2025 年 10 月 29 日召开第二届董事会第十九次会议，审议通过了《关于拟变更会计师 事务所的议案》，同意聘任安永华明为公司 2025 年度审计机构，本议案尚需提 交公司股东会审议。现将具体内容公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第四次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 证券代码：301087 证券简称：可孚医疗 公告编号：2025-080 可孚医疗科技股份有限公司 关于召开 2025 年第四次临时股东会的通知 4、会议时间： （1）现场会议时间：2025年11月14日（星期五）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月14日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为2025年11月14日9:15至15:00的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025年11月6日（星期四） 7、出席对象： ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-076 可孚医疗科技股份有限公司 第二届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第二届董事会第十九次会 议于 2025 年 10 月 25 日以电子邮件的方式发出会议通知，会议于 2025 年 10 月 29 日上午 8:30 以通讯方式召开。会议应出席董事 7 名，实际出席董事 7 人，公 司高级管理人员列席了会议。本次会议由董事长张敏先生主持。会议的召集和召 开符合《中华人民共和国公司法》等法律法规和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于公司<2025 年第三季度报告>的议案》 公司 2025 年第三季度报告全文及其摘要遵循相关法律法规及规范性文件要 求编制，报告内容真实、准确、完整地反映了公司 2025 年第三季度的经营情况， 不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥902,027,920.61, representing a year-over-year increase of 30.72%[5] - Net profit attributable to shareholders was ¥92,829,784.04, up 38.68% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses increased by 62.68% to ¥85,802,669.67[5] - The basic earnings per share for the quarter was ¥0.46, reflecting a growth of 39.39% year-over-year[5] - Total revenue for the third quarter reached ¥2,397,791,920.73, an increase of 6.63% compared to ¥2,248,651,846.83 in the previous year[28] - The net profit for the current period is CNY 259,507,645.73, an increase from CNY 251,937,817.59 in the previous period, representing a growth of approximately 3.5%[29] - The basic earnings per share for the current period is CNY 1.28, up from CNY 1.24 in the previous period, which is an increase of about 3.2%[30] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥6,540,292,345.50, a 1.83% increase from the end of the previous year[5] - Current liabilities rose to ¥1,637,988,672.10, compared to ¥1,361,721,170.48, representing an increase of 20.29%[26] - The company’s total liabilities increased significantly, with other current liabilities rising by 6437.58% to ¥10,703,673.10, mainly due to an increase in endorsed but not yet due non-A rated notes[10] - The total equity attributable to shareholders decreased to ¥4,713,657,384.44 from ¥4,796,596,352.25, a decline of 1.73%[27] Cash Flow - The company reported a net cash flow from operating activities of ¥589,991,388.19, which is a 35.36% increase compared to the previous period[13] - The cash flow from operating activities net amount is CNY 589,991,388.19, up from CNY 435,875,379.93, indicating a significant increase of approximately 35.4%[31] - The cash and cash equivalents balance increased to ¥1,297,129,950.07 from ¥1,278,679,967.98, reflecting a growth of 1.04%[25] - The cash and cash equivalents at the end of the period amount to CNY 1,211,867,558.21, down from CNY 1,682,965,410.24, indicating a decrease of approximately 28.0%[32] - The net cash flow from investing activities is CNY -166,212,273.98, slightly worse than CNY -157,365,720.23 in the previous period, showing a decline of about 5.4%[32] - The company’s total liabilities increased, with cash outflow for financing activities amounting to CNY 1,486,487,292.43, compared to CNY 1,028,640,120.66 in the previous period, reflecting an increase of approximately 44.4%[32] Investments and Shareholder Information - The company’s long-term equity investments increased by 48.99% to ¥91,522,254.96, attributed to new equity investments made during the period[10] - The largest shareholder, a domestic non-state legal entity, holds 40.73% of shares, totaling 85,079,923 shares[15] - The top 10 shareholders include several investment partnerships, with the largest holding being 85,079,923 shares[16] - The company has a share buyback account holding 5,699,731 shares, representing 2.73% of total equity[16] - The total number of restricted shares at the end of the period is 97,498 shares after adjustments[19] - The company has no preferred shareholders or changes in preferred shareholder status[17] Future Plans and Strategies - The company plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance global strategy and brand recognition[20] - A cash dividend of 6 RMB per 10 shares will be distributed, totaling 121,918,361.40 RMB (including tax) for the 2025 semi-annual profit distribution[21] - The company plans to expand its market presence and invest in new product development, focusing on innovative technologies[26] Operating Costs and Expenses - Total operating costs amounted to ¥2,140,937,840.58, up from ¥1,972,854,349.55, reflecting a year-over-year increase of 8.52%[28] - Research and development expenses were ¥61,091,966.84, a decrease of 12.5% from ¥69,408,244.31 in the previous year[28]

可孚医疗科技股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为进一步规范可孚医疗科技股份有限公司（以下简称"公司"）选 聘（含续聘、改聘，下同）会计师事务所的行为，切实维护股东利益，提高审 计工作和财务信息的质量，依据《中华人民共和国公司法》《国有企业、上市 公司选聘会计师事务所管理办法》等法律法规、规范性文件和《可孚医疗科技 股份有限公司章程》（以下简称《公司章程》）等有关规定，结合公司实际情 况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司 聘任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，可以 比照本制度执行。 第三条 公司选聘会计师事务所应当经董事会审计委员会（以下简称"审 计委员会"）审议同意后，提交董事会和股东会审议。 第二章 选聘会计师事务所的执业质量要求 第四条 公司选聘的会计师事务所应当具备下列条件： （一）具有独立的主体资格，具备国家行业主管部门和中国证监会规定的 开展证券期货相关业务所需的执业资格； （二）具有固定的工作场所、健全的组织机构和完善的内部管理和控 ...